Thank you very much, Mr. Chair.
Thanks to the witnesses. Your statements were very interesting.
I'm going to start with you, Mr. Rebeck.
You raised the issue of a universal pharmacare program. What we have heard from some business groups as we've gone across the country is that they would prefer to fill in the gaps that exist in the current series of drug programs, which would make it very much more like the patchwork that we see in the United States. Can you give us a sense of why it's important to have a universal pharmacare program rather than just trying to fill in some of the holes?